---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116364"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:03:56.703745+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports Q3 net loss $3.0M; complete response in first MT-601 lymphoma patient

## Summary
- Net loss of $3.0M for Q3 2023 vs $6.9M in Q3 2022; R&D expenses down to $2.0M from $3.6M.
- First lymphoma patient treated with MT-601 in Phase 1 APOLLO trial achieved complete metabolic response after failing CAR T therapy.
- MT-401 (zedenoleucel) received Orphan Drug Designation from EMA for AML; clinical trial for MT-401 off-the-shelf expected in 2024.
- Cash and cash equivalents of $17.5M as of September 30, 2023.

## SEC filing metadata
- accession: 0001104659-23-116364
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/0001104659-23-116364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/tm2330322d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116364
- JSON: https://secwatch.observer/filing/0001104659-23-116364.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116364.txt

## Key facts
- Earnings Releases
  Marker Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income ($3.0) million.
  - Period: the third quarter ended September 30, 2023
  - Net income: ($3.0) million
  - Result: reported results
  source text: Marker reported a net loss of ($3.0) million for the quarter ended September 30, 2023, compared to a net loss of ($6.9) million, inclusive of the $(1.2) million loss from discontinued operations, reflected in the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/0001104659-23-116364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.